Elimination of lymphatic filariasis

Lancet

Volumn 368, Issue 9533, 2006, Pages 362-363

  Michael, Edwin ^a   Malecela Lazaro, Mwele N ^b   Kazura, James W ^c  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (Tanzania)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; DIETHYLCARBAMAZINE;

DIAGNOSTIC ACCURACY; HUMAN; LETTER; LYMPHATIC SYSTEM DISEASE; MICROFILARIA; MICROFILARIASIS; PARASITE TRANSMISSION; PATIENT MONITORING; PRIORITY JOURNAL; PUBLIC HEALTH; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

EID: 33746274635     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)69100-9     Document Type: Letter

References (4)

1. Ramzy R., El Setouhy M., Helmy H., et al. Effect of yearly mass drug administration with diethylcarbamazine and albendazole on bancroftian filariasis in Egypt: a comprehensive assessment. Lancet 367 (2006) 992-999
2. Molyneux D. Elimination of transmission of lymphatic filariasis in Egypt. Lancet 367 (2006) 966-968
3. Michael E., Malecela-Lazaro M., Kabali C., Snow L., and Kazura J. Mathematical models and lymphatic filariasis control: endpoints and optimal interventions. Trends Parasitol 22 (2006) 226-233
4. Nicolas L. New tools for diagnosis and monitoring of bancroftian filariasis parasitism: the Polynesian experience. Parasitol Today 13 (1997) 370-375